Live Feeds
● TRACKER Updated 22d ago · 8 sources tracked

Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial

Moderna and Merck announced Wednesday that their experimental mRNA vaccine prevented melanoma from returning or spreading in high-risk patients. The personalized treatment successfully cleared phase 3 clinical trials, which is the final requirement before FDA approval. While the news initially drove a surge in Moderna stock, the company saw a 24% price drop on Thursday as the rally faded. The vaccine was used in combination with Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma to improve recurrence-free and distant metastasis-free survival.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The experimental mRNA vaccine cleared phase 3 clinical trials.
  • ✓ Moderna and Merck developed the vaccine to keep melanoma from returning or spreading in high-risk patients.
  • ✓ The vaccine was administered alongside Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma.
🛡️ Source Corroboration: 8 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

The vaccine has now officially cleared phase 3 clinical trials and Moderna stock experienced a 24% pullback following an initial surge.

Live updates

  1. Moderna and Merck melanoma vaccine clears phase 3 trials

    Moderna and Merck announced Wednesday that their experimental mRNA vaccine prevented melanoma from returning or spreading in high-risk patients. The personalized treatment successfully cleared phase 3 clinical trials, which is the final requirement before FDA approval. While the news initially drove a surge in Moderna stock, the company saw a 24% price drop on Thursday as the rally faded. The vaccine was used in combination with Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma to improve recurrence-free and distant metastasis-free survival.

    Why it matters

    Personalized mRNA vaccines target specific mutations in a patient's tumor to prime the immune system. This trial focused on high-risk skin cancer patients to reduce the likelihood of the disease returning after surgery. FDA approval would mark a shift toward individualized cancer immunotherapy.

    What is confirmed

    • The experimental mRNA vaccine cleared phase 3 clinical trials.
    • Moderna and Merck developed the vaccine to keep melanoma from returning or spreading in high-risk patients.
    • The vaccine was administered alongside Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma.

    Still unconfirmed

    • Moderna stock fell 24% on Thursday after an initial rally.
    • An October catalyst will determine the next movement for Moderna stock.

    What to watch next

    • FDA approval decision for Intismeran Autogene
    • Moderna stock performance following October catalyst
    Sources used for this update (4)
    1. www.nationalgeographic.com — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
    2. financefeeds.com — Moderna (MRNA) Gave Back a Quarter of Its Cancer-Vaccine Surge, Here’s What Wall Street Is Waiting For
    3. medicalxpress.com — Personalized vaccine helped melanoma patients stay cancer-free longer, drugmakers say
    4. consent.yahoo.com — Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
    confidence 90%

  2. Moderna surges as Merck-partnered melanoma vaccine succeeds in large trial

    Moderna and Merck's mRNA cancer vaccine, tested in a late-stage melanoma trial, met endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. The vaccine, known as Intismeran Autogene, was administered alongside Merck's KEYTRUDA. The trial results showed a significant reduction in cancer recurrence.

    Why it matters

    The success of this vaccine could mark a significant advancement in cancer treatment, offering new hope for patients with advanced melanoma. Melanoma is a serious form of skin cancer that can be fatal if not caught early. Current treatments have limitations, and a vaccine that can prevent recurrence would be a major breakthrough.

    What is confirmed

    • Moderna and Merck's mRNA cancer vaccine succeeded in a late-stage melanoma trial
    • The vaccine, Intismeran Autogene, was tested alongside Merck's KEYTRUDA
    • The trial met endpoints of recurrence-free survival and distant metastasis-free survival

    What to watch next

    • Full results of the Phase 3 INTerpath-001 trial
    • Regulatory approval and market availability of the vaccine
    • Impact on current melanoma treatment options and patient outcomes
    Sources used for this update (5)
    1. STAT — Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
    2. The Washington Post — Cancer treatment could face landmark moment with promising vaccine
    3. Reuters — Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
    4. Reuters — Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results: Instant View
    5. Business Wire — Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano
    confidence 85%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community